One To Watch

Alumis

A clinical-stage biopharmaceutical company based in South San Francisco, California. The company operates as an R&D organization focused on immune-mediated diseases, with clinical trials conducted through external sites in the U.S. and internationally.

Founding and History

Alumis was established to build a pipeline of oral therapies for immune-mediated diseases. The company became publicly traded in June 2024 and lists on Nasdaq under the ticker ALMS. In early January 2026, Alumis reported topline results from its Phase III plaque psoriasis program for its lead asset, marking its first late-stage readout as a public company.

Therapy Areas and Focus

Alumis focuses on immune-mediated diseases. Its most advanced development work is in dermatology, with plaque psoriasis as the lead indication. The company is also developing its lead program in systemic lupus erythematosus.

Technology Platforms and Modalities

Alumis develops oral small-molecule immunology medicines. Its lead program, envudeucitinib (formerly ESK-001), is a highly selective allosteric inhibitor of TYK2. The company positions TYK2 inhibition as a mechanism to modulate inflammatory signaling relevant to multiple immune-mediated diseases.

Key Personnel

Alumis is led by a CEO and executive team spanning clinical development, medical, research, finance, and operations, consistent with a late clinical-stage immunology company advancing pivotal programs.

Strategic Partnerships

Alumis’ lead program development has been advanced internally. The company’s operating model relies on external clinical and manufacturing partners typical for a clinical-stage biopharmaceutical company.

FAQ Section

Alumis is developing oral small-molecule therapies for immune-mediated diseases, with a lead program built around selective, allosteric TYK2 inhibition.

The company’s disclosed focus is immune-mediated disease, led by plaque psoriasis and including systemic lupus erythematosus.

Envudeucitinib, a TYK2 inhibitor, is Alumis’ lead program. It is in Phase III development for moderate-to-severe plaque psoriasis and in clinical development for systemic lupus erythematosus.

In January 2026, Alumis reported topline Phase III results from its ONWARD program evaluating envudeucitinib in moderate-to-severe plaque psoriasis and discussed plans to pursue regulatory filings based on that dataset.

Alumis has reported Phase II durability data in plaque psoriasis and, most recently, topline Phase III outcomes from the ONWARD program in plaque psoriasis. Public communications have emphasized skin clearance endpoints and overall tolerability typical for late-stage psoriasis development.

Following the Phase III ONWARD topline readout in January 2026, Alumis has stated an intention to advance envudeucitinib toward regulatory submission for plaque psoriasis. Clinical development in systemic lupus erythematosus remains an additional pipeline priority.

Alumis is run by an executive team with experience in immunology drug development and clinical execution, overseeing a transition from mid-stage clinical development into pivotal readouts and regulatory preparation.

Want to Update your Company's Profile?